Trials / Completed
CompletedNCT01442727
Selenium in the Treatment of Arsenic Toxicity and Cancers
Selenite in the Detoxification of Arsenic and the Prevention of Arsenical Melanosis and Cancers Amongst Bangladeshi Arsenicosis Patients: A 48-week, Randomized, Double-blinded, Placebo-controlled Phase III Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 819 (actual)
- Sponsor
- Texas Tech University · Academic / Other
- Sex
- All
- Age
- 12 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
Context: Approximately 100 million people throughout the world consume water contaminated with arsenic at levels above carcinogenic thresholds, including 40 million in Bangladesh alone, with up to one-fourth of deaths attributed to arsenic exposure in the worst-affected regions. There are no proven therapies for treating chronic arsenic toxicity or for preventing arsenical cancers. Selenium has been known to counter arsenic toxicity in a variety of animal models. The investigators have recently shown in animals and humans that this effect is mediated by the formation of \[(GS)2AsSe\]- , the seleno-bis(S-glutathionyl) arsinium ion, which is then rapidly excreted via the hepatobiliary system. Concurrently, two Phase II studies in China and Bangladesh have suggested clinical benefit to selenium supplementation in arsenicosis patients. Objective: To assess whether daily selenium supplementation counters arsenic toxicity in patients exposed to drinking water arsenic. If proven effective, selenium supplementation might be safely and cost-effectively implemented in the worst-affected localities.
Conditions
- Arsenical Melanosis
- Arsenical Keratosis
- Arsenical Cancers
- Arsenicosis
- Arsenic Exposure
- Arsenic Toxicity
- Arsenic Poisoning
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sodium selenite | 200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast. |
| DRUG | placebo | dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2011-09-28
- Last updated
- 2011-10-07
Locations
1 site across 1 country: Bangladesh
Source: ClinicalTrials.gov record NCT01442727. Inclusion in this directory is not an endorsement.